Immuron's Unique Technology Platform
Immuron is not a one product biotechnology company. Its core technology is a platform for the delivery of a wide variety of known and currently unexplored antibodies that can affect the Immune system in the gut and create disease. IMM-124E for example targets 18 strains of E- Coli and other gram negative or LPS bacteria. IMM-529 targets Toxin B, produced by Clostridium Difficile in the gut causing uncontrolled diarrhoea.
Some of the most common chronic diseases such as diabetes, obesity and non-alcoholic steatohepatitis (NASH) are associated with increased peripheral inflammation. Immuron is targeting these diseases through its novel hyper-immune oral platform.
The human gut is the largest lymphoid organ in the body. Composed of luminal and components within the gut wall, this system is designed to identify exogenous antigens, discriminate between "friend and foe" to which a systemic response is in-turn generated.
Immuron has developed a unique oral immunotherapy platform altering the immunological balance by orally administered safe compounds. Immuron oral compound affects the gut's immune system by multiple pathways relieving immunological "tension" to decrease inflammation at sites where it is in excess.
Immuron's oral immuno-therapy potentially addresses a wide range of diseases. Furthermore, Immuron's proprietary compounds are not absorbed through the gut wall hence generate an anti-inflammatory effect at site through a natural pathway thus demonstrating an extraordinary safety and tolerability profiles.
Immunotherapy is defined as "treatment of disease by inducing, enhancing, or suppressing an immune response”. Immuron’s oral immunotherapy uses the inherent ability of the gastro-intestinal (GI) tract's immune system to control unwanted systemic immune responses, by inducing regulatory T cells in an antigen-specific manner. The gut mucosal immune system is the largest lymphoid organ in the body and differentiates antigenic signals against the high background “noise” of food and bacterial antigens. This does not involve general immune suppression and thus does not have serious side effects such as increased infection susceptibility.